Mar 29, 2011

Kalbe Farma FY10 net income up 38.46%

Indonesian giant pharmaceutical maker PT Kalbe Farma Tbk (KLBF) today reported a 38.46% increase in earning last year on the back of higher net sales.
In an official financial statement submitted to Indonesia Stock Exchange (IDX) today, Kalbe Farma posted IDR1.29 trillion net income last year from IDR929 billion in the previous year.
Income from operations increased 14.01% to IDR1.79 trillion from IDR1.57 trillion. However, Kalbe Farma's operating margin was flat at the level of 17%.
Gross profit rose 14.01% to IDR5.17 trillion from IDR4.51 trillion. Net sales increased 12.54% to IDR10.23 trillion from IDR9.09 trillion. The largest contributor for the net sales was distribution and packaging business with IDR3.21 trillion revenue.
Prescription pharmaceutical, consumer health, and nutritionals segments contributed revenue of IDR2.21 trillion, IDR1.73 trillion, and IDR1.94 trillion respectively.
PT Gira Sole Prima owns 10.17% shareholding in Kalbe Farma, PT Santa Seha Sanadi owns 9.62%, and PT Diptanala Bahana holds 9.49% stake.
PT Lucasta Murni Cemerlang, PT Ladang Ira Panen, PT Bina Artha Charisma, and public shareholders own 9.47%, 9.22%, 8.67%, and 43.36% respectively.

Disclosure: No position at the stock mentioned above.

Print This Article

No comments: